Fibrin Degradation Products, Medical Tests, NE - CHI Health, Omaha

Health Encyclopedia - Test

Search Health Information   

 

Fibrin degradation products

Definition

Alternative Names

FDPs; FSPs; Fibrin split products; Fibrin breakdown products

How the Test is Performed

How to Prepare for the Test

How the Test will Feel

Why the Test is Performed

This test is done to see if your clot-dissolving (fibrinolytic) system is working properly. Your doctor may order this test if you have signs of disseminated intravascular coagulation (DIC) or another clot-dissolving disorder.

Normal Results

The result is normally less than 10 micrograms per milliliter (mcg/mL).

Note: Normal value ranges may vary slightly among different laboratories. Talk to your doctor about the meaning of your specific test results.

The example above shows the common measurements for results for these tests. Some laboratories use different measurements or may test different specimens.

What Abnormal Results Mean

Increased FDPs may be a sign of primary or secondary fibrinolysis (clot-dissolving activity) due to a variety of causes, including:

Risks

  • Excessive bleeding
  • Fainting or feeling light-headed
  • Hematoma (blood accumulating under the skin)
  • Infection (a slight risk any time the skin is broken)

References

Brummel-Ziedins K. Mann KG. Molecular basis of blood coagulation. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Saunders Elsevier; 2012:chap 128.

Levi M. Disseminated intravascular coagulation. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Saunders Elsevier; 2012:chap 128.

Schafer AI. Hemorrhagic disorders: Disseminated intravascular coagulation, liver failure, and vitamin K deficiency. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 178.


Review Date: 3/3/2013
Reviewed By: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Black, Stephanie Slon, and Nissi Wang.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com